EI
ATXI

EAM Investors’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

EAM Investors’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-64
Closed -$778K – 400
2020
Q3 		$778K Sell
64
-22
-26% -$267K 0.18% 242
2020
Q2 		$1.04M Hold
86
– – 0.23% 190
2020
Q1 		$861K Buy
86
+4
+5% +$40.1K 0.27% 160
2019
Q4 		$887K Sell
82
-18
-18% -$126K 0.2% 215
2019
Q3 		$669K Buy
100
+33
+49% +$225K 0.18% 209
2019
Q2 		$474K Sell
67
-15
-18% -$86.8K 0.12% 239
2019
Q1 		$437K Buy
+82
New +$523K 0.11% 244

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM Investors's ATXI Position: Q4 2020 in Review

EAM Investors sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2020, closing a stake of 64 shares — an estimated $778K sold.

EAM Investors first reported a position in ATXI in Q1 2019 and held it in 7 quarters. The position peaked at $1.04M in Q2 2020. 33 funds tracked by Wall St. Rank hold ATXI as of Q4 2020.

  • EAM Investors reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • EAM Investors sold 64 Avenue Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $778K.
  • EAM Investors first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
  • EAM Investors's Avenue Therapeutics, Inc. Common Stock position peaked at $1.04M in Q2 2020.
  • 33 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2020.

Based on EAM Investors's 13F filing for Q4 2020, filed 11 Feb 2021.